Amunix is an industry leader in the discovery and development of long-acting protein- and peptide therapeutics. Founded in 2006, Amunix’ pipeline products are based on its proprietary XTEN® half-life extension, XDC drug-conjugate delivery and ProTIA pro-drug, bispecific T cell engager platform technologies. Located in Mountain View, CA, Amunix is progressing the development of its internal pipeline and also has ongoing collaborations with a number of established and emerging biopharma corporations harnessing these delivery technologies in a wide range of therapeutic areas, delivering improved pharmaceutical safety, efficacy and dosing.
State of Ownership
học viện thẩm mỹ prana, học viện thẩm mỹ prana
Business Development Executive, Nature Publishing Group, Springer Nature
Sales Account Executive, Springer Nature
Director of Sales , SOLABS
Managing Director, Thoroughly Good Consulting
Project Development Manager, Cancer Research Technology